Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605691 | 1.00 | ALDH1A1 (0.32) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL5606210 | 0.75 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL6557553 | 0.75 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL14458137 | 0.75 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL5710091 | 0.61 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL11784222 | 0.61 | ABCB11 (0.32) | LMNAHIF1A | |
| SCHEMBL19649525 | 0.60 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL14458046 | 0.60 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2ALMNAHIF1A | |
| SCHEMBL124554 | 0.60 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL11219012 | 0.60 | TSHR (0.31) | ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247752-B2 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMACEUTICALS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | CARDAX PHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060183185-A1 | Method for the synthesis of astaxanthin | CARDAX PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060178538-A1 | Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060167319-A1 | Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060155150-A1 | Methods for the synthesis of lutein | CARDAX PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060111580-A1 | Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids | CARDAX PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060088905-A1 | Methods for the synthesis of zeazanthin | CARDAX PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060088904-A1 | Methods for the synthesis of astaxanthin | CARDAX PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2006039685-A2 | METHODS FOR SYNTHESIS OF CHIRAL INTERMEDIATES OF CAROTENOIDS, CAROTENOID ANALOGS, AND CAROTENOID DERIVATIVES | HAWAII BIOTECH, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088904-A1 | Methods for the synthesis of astaxanthin | HSD17B7, CYP51A1, HSD11B1 | ALDH1A1 287/4885MEN1 3207/4885KMT2A 964/4885 |
| US-20060178538-A1 | Methods for the synthesis of chiral dihydroxy intermediates useful for the chiral synthesis of carotenoids | HSD17B7, DHPS, DHCR7 | ALDH1A1 327/4885MEN1 2220/4885KMT2A 1183/4885 |
| US-20060167319-A1 | Methods for the synthesis of unsaturated ketone intermediates useful for the synthesis of carotenoids | DHPS, HSD17B7, COASY | ALDH1A1 436/4885MEN1 2814/4885KMT2A 1227/4885 |
| US-20060155150-A1 | Methods for the synthesis of lutein | LSS, DHPS, CYP51A1 | ALDH1A1 442/4885MEN1 1871/4885KMT2A 626/4885 |
| US-20060183947-A1 | Stereoselectively reducing 2,6,6-trimethyl-2-cyclohexene-1,4-dione with an optically active chiral catalyst to form an optically active hydroxycyclohexenone, contacting the product with a reducing agent to form an optically active diol, and using the diol to form astaxanthin | DHCR7, HSD17B7, HSD11B1 | ALDH1A1 242/4885MEN1 2802/4885KMT2A 1057/4885 |
| US-20060088905-A1 | Methods for the synthesis of zeazanthin | DHPS, CYP51A1, HSD17B7 | ALDH1A1 667/4885MEN1 1291/4885KMT2A 406/4885 |
| US-20060111580-A1 | Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids | DHPS, DHCR7, HSD17B7 | ALDH1A1 374/4885MEN1 2223/4885KMT2A 1226/4885 |
| US-20060183185-A1 | Method for the synthesis of astaxanthin | SQLE, HSD17B7, CYP51A1 | ALDH1A1 377/4885MEN1 3340/4885KMT2A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.